H3B-8800 (H3B8800)

H3B-8800 (H3B8800) Chemische Eigenschaften,Einsatz,Produktion Methoden

• Verwenden

  H3B-8800 is a potent and orally active SF3B splicing modulator. H3B-8800 direct interaction with the SF3b complex and shows anti-cancer activity. H3B-8800 has the potential for the research of acute myeloid leukemia (AML) with SF3B1 mutant[1].

• in vivo

  H3B-8800 (2, 4 mg/kg; p.o.; daily) shows anti tumor activity in AML derived xenografts (PDXs) with a mutation in SF3B1^[1].

  Animal Model:	6-8 weeks, female NSG or CB17-SCID mice (K562 cells with SF3B1WT or SF3B1K700E)[1]
  Dosage:	2, 4 mg/kg
  Administration:	P.o.; daily
  Result:	Resulted in antileukemic efficacy and splicing modulation in mice bearing AML patient-derived xenografts (PDXs) with a mutation in SF3B1 but had little effect in mice bearing SF3B1WT AML PDXs, significantly reduced leukemic burden relative in SF3B1K700E PDX.

• Einzelnachweise

  [1] Seiler M, et al. H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers. Nat Med. 2018 May;24(4):497-504. DOI:10.1038/nm.4493

H3B-8800 (H3B8800) Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global(30)Suppliers